Key result
Thrombolytic agents provide more rapid clot resolution, lung reperfusion, and hemodynamic reversal compared to heparin in patients with venous thromboembolism.
Why the study?
Do thrombolytic agents improve clot resolution and hemodynamics compared to heparin in patients with venous thromboembolism?
Do thrombolytic agents improve clot resolution and hemodynamics compared to heparin in patients with venous thromboembolism?
Answers are grounded in this paper and cite their sources.
Thrombolytic therapy offers short- and long-term benefits over heparin in venous thromboembolism by improving clot resolution, hemodynamics, and preserving venous valves.
The use of thrombolytic agents in venous thromboembolism has been shown to be highly effective. Patients treated with lytic agents show more rapid clot resolution and lung reperfusion and more rapid and greater reversal of the abnormal hemodynamic responses to pulmonary embolism than patients receiving heparin. Moreover, lytic therapy removes thromboemboli more completely from the pulmonary microcirculation, whereas residual thromboemboli tend to accumulate with heparin therapy. In addition, lytic therapy tends to preserve the venous valves, whereas distortion and destruction occur with heparin therapy. Hence, lytic therapy confers a number of short- and long-term benefits not observed with heparin therapy.
No takes yet. Share an insight, caveat, or question.
Arthur A. Sasahara (1982) conducted a review in Venous thromboembolism. Thrombolytic agents vs. Heparin was evaluated. Thrombolytic agents provide more rapid clot resolution, lung reperfusion, and hemodynamic reversal compared to heparin in patients with venous thromboembolism.
Synapse has enriched 10 related papers. Consider them for comparative context: